Biotech Values

[DewDiligence]

VSTM blurb in today’s Boston Globe:

http://www.bostonglobe.com/business/2012/05/22/after-coup-verastem-navigates-choppy-waters-after-funding-coup-choppy-waters/S33ijR2yxJzhH7htBRG8YM/story.html

The ultimate goal is to provide patients with a cocktail containing two drugs: one attacking cancer non-stem cells and the other targeting the stem cells. A number of other companies, ranging from start-ups like OncoMed Pharmaceuticals Inc. in Redwood City, Calif., to drug giants such as GlaxoSmithKline in Britain, are also targeting tumor-initiating cells.